Abbott's Hep-C Pressures All Hep-C Rivals (ABT, RIGL, GILD, VRTX, IDIX)

Health and Healthcare

Published: April 4, 2012 1:28 pm

Last Updated: April 27, 2020 3:08 pm

News from Abbott Laboratories (NYSE: ABT) on its positive Phase II study results from two different interferon-free hepatitis C treatment has the entire drug sector up in arms as it pertains to Hepatitis C drugs. The 91%, 93%, and 95% response rates that were initially seen in the report were more than impressive. The news is spooking investors in other Hepatitis C drug players as you can see:

Rigel Pharmaceuticals (NASDAQ: RIGL) has a study under way and its shares are down 4% at $7.95.

Gilead Sciences Inc. (NASDAQ: GILD) has already taken it on the chin once and maybe it should feel lucky that its drop is only 1% at $47.61 so far today.

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is down 1.5% at $41.17 on the day.

Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) is the worst of the lot that we have seen with a drop of 14.4% at $8.75.

Investors over the longer-term should be reminded that unless Abbott is allowed to skip a lot of the testing that it could still be quite some time before its Hepatitis C treatment even comes up for the traditional FDA approval process. We are nearly in mid-2012 already, and that could put the time frame out to 2014 or even longer.

JON C. OGG

It’s Your Money, Your Future—Own It (sponsor)

Retirement can be daunting, but it doesn’t need to be.

Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter!

Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.